BioAge Labs, Inc. (BIOA)
(Delayed Data from NSDQ)
$19.73 USD
-0.52 (-2.57%)
Updated Oct 2, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIOA 19.73 -0.52(-2.57%)
Will BIOA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BIOA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BIOA
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
IPO Roundup: FrontView REIT, StandardAero and more
Obesity Drug Developer BioAge Makes Nasdaq Debut
U.S. IPO Weekly Recap: 3 Sizable Deals Trade Up
Biotech IPOs return as sector recovers after funding overhang